Literature DB >> 20486493

[Plasmodium knowlesi--the fifth species causing human malaria].

Anu Kantele1, Sakari Jokiranta.   

Abstract

Four species have been known to bring on human malaria, the most severe disease being caused by Plasmodium falciparum. In 2007, after returning from Malaysia, a Finnish tourist was found to be infected with a fifth Plasmodium species, P. knowlesi which usually infects macaques. Over the past few years, hundreds of human cases have been found in Malaysia. The clinical disease caused by P. knowlesi appears less severe than P. falciparum infection, but more severe than infection with other malaria-causing species. Diagnosis is based both on PCR and microscopy. P. knowlesi is currently. considered as the fifth species causing malaria in humans.

Entities:  

Mesh:

Year:  2010        PMID: 20486493

Source DB:  PubMed          Journal:  Duodecim        ISSN: 0012-7183


  4 in total

1.  Prevalence and Risk Factors for Sulfadoxine Antibody Among Patients Undergoing Treatment for Malaria in Benin City, Nigeria.

Authors:  Kingsley Ikuoyogie; Helen Oroboghae Ogefere; Richard Omoregie
Journal:  Oman Med J       Date:  2017-05

2.  Identification and characterization of DNA endonucleases in Plasmodium falciparum 3D7 clone.

Authors:  Ning Jiang; Zhiwei Tu; Yiwei Zhang; Jianping Li; Ying Feng; Na Yang; Xiaoyu Sang; Qijun Chen
Journal:  Malar J       Date:  2018-06-18       Impact factor: 2.979

3.  Accurate identification of the six human Plasmodium spp. causing imported malaria, including Plasmodium ovale wallikeri and Plasmodium knowlesi.

Authors:  Adriana Calderaro; Giovanna Piccolo; Chiara Gorrini; Sabina Rossi; Sara Montecchini; Maria Loretana Dell'Anna; Flora De Conto; Maria Cristina Medici; Carlo Chezzi; Maria Cristina Arcangeletti
Journal:  Malar J       Date:  2013-09-13       Impact factor: 2.979

4.  Intermittent preventive treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine regimens in schoolchildren of the Democratic Republic of Congo: a study protocol for a randomized controlled trial.

Authors:  Joachim Yorokpa Doua; Junior Matangila; Pascal Lutumba; Jean-Pierre Van Geertruyden
Journal:  Trials       Date:  2013-09-24       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.